Jose A. Colina

Jose A. Colina

Auto-generated profile, based on publicly available information

Jose A. Colina

University of Michigan 1 Department of Pathology Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
RARita A. Avelar
Rita A. Avelar
AAAmy J. Armstrong
Amy J. Armstrong
GCGracie Carvette
Gracie Carvette
RGRiya Gupta
Riya Gupta
NPNoah Puleo
Noah Puleo
ADAnalisa DiFeo
Analisa DiFeo
High-grade serous carcinoma (HGSC) is the most common and lethal ovarian cancer subtype. PARP inhibitors (PARPi) have become the mainstay of HGSC-targeted therapy, given that these tumors are driven by a high degree of genomic instability (GI) and homologous recombination (HR) defects. Nonetheless, approximately 30% of patients initially respond to treatment, ultimately relapsing with resistant disease. Thus, despite recent advances in drug development and an increased understanding of genetic alterations driving HGSC progression, mortality has not declined, highlighting the need for novel therapies. Using a small-molecule activator of protein phosphatase 2A (PP2A; SMAP-061), we investigated the mechanism by which PP2A stabilization induces apoptosis in patient-derived HGSC cells and xenograft (PDX) models alone or in combination with PARPi. We uncovered that PP2A genes essential for cellular transformation (B56α, B56γ, and PR72) and basal phosphatase activity (PP2A-A and -C) are heterozygously lost in the majority of HGSC. Moreover, loss of these PP2A genes correlates with worse overall patient survival. We show that SMAP-061–induced stabilization of PP2A inhibits the HR output by targeting RAD51, leading to chronic accumulation of DNA damage and ultimately apoptosis. Furthermore, combination of SMAP-061 and PARPi leads to enhanced apoptosis in both HR-proficient and HR-deficient HGSC cells and PDX models. Our studies identify PP2A as a novel regulator of HR and indicate PP2A modulators as a therapeutic therapy for HGSC. In summary, our findings further emphasize the potential of PP2A modulators to overcome PARPi insensitivity, given that targeting RAD51 presents benefits in overcoming PARPi resistance driven by BRCA1/2 mutation reversions. Watch the interview with Analisa DiFeo, PhD, recipient of the 2025 Molecular Cancer Therapeutics Award for Outstanding Journal Article: https://vimeo.com/1100470225

15 June 2026
Verified
Other
Open access
PDF file
JCJose A. Colina
Jose A. Colina
MRMaria Sol Recouvreux
Maria Sol Recouvreux
ASAlexander M. Sobeck
Alexander M. Sobeck
BJBenjamin K. Johnson
Benjamin K. Johnson
YLYinzhi Lin
Yinzhi Lin
ADAnalisa DiFeo
Analisa DiFeo
STING overexpression in murine oviductal epithelial (MOE) cells enhances oxidative stress–induced signaling and cell death responses

15 June 2026
Verified
Other
Open access
PDF file
JCJose A. Colina
Jose A. Colina
MRMaria Sol Recouvreux
Maria Sol Recouvreux
ASAlexander M. Sobeck
Alexander M. Sobeck
BJBenjamin K. Johnson
Benjamin K. Johnson
YLYinzhi Lin
Yinzhi Lin
ADAnalisa DiFeo
Analisa DiFeo
STING activation and DNA damage in murine reproductive tracts under basal and superovulated conditions

15 June 2026
Verified
Other
Open access
PDF file
JCJose A. Colina
Jose A. Colina
MRMaria Sol Recouvreux
Maria Sol Recouvreux
ASAlexander M. Sobeck
Alexander M. Sobeck
BJBenjamin K. Johnson
Benjamin K. Johnson
YLYinzhi Lin
Yinzhi Lin
ADAnalisa DiFeo
Analisa DiFeo
STING1 expression is most highly expressed in ciliated cells of the FTE

15 June 2026
Verified
Other
Open access
PDF file
JCJose A. Colina
Jose A. Colina
MRMaria Sol Recouvreux
Maria Sol Recouvreux
ASAlexander M. Sobeck
Alexander M. Sobeck
BJBenjamin K. Johnson
Benjamin K. Johnson
YLYinzhi Lin
Yinzhi Lin
ADAnalisa DiFeo
Analisa DiFeo
Multiplex IHC staining on a tumor microarray containing normal FTE and various stage HGSC samples

15 June 2026
Verified
Other
Open access
JCJose A. Colina
Jose A. Colina
MRMaria Sol Recouvreux
Maria Sol Recouvreux
ASAlexander M. Sobeck
Alexander M. Sobeck
BJBenjamin K. Johnson
Benjamin K. Johnson
YLYinzhi Lin
Yinzhi Lin
ADAnalisa DiFeo
Analisa DiFeo
Human IHC antibodies used to stain normal, precursor, and ovarian tumors